Boehringer In­gel­heim is think­ing in block­buster terms as it throws its hat in­to the ever-widen­ing CD47 ring

Boehringer In­gel­heim is jump­ing on­to the CD47 “don’t-eat-me” path­way.

The Ger­man com­pa­ny is pay­ing $37 mil­lion in cash and near-term mile­stones to grab rights to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER